Skip to main
COCH
COCH logo

COCH Stock Forecast & Price Target

COCH Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Envoy Medical Inc. presents a compelling investment opportunity due to its attractive valuation and significant upside potential, underscored by a recent net present value analysis. With approximately 50% of the hearing device market being international, the company is well-positioned to capitalize on this expansive growth opportunity. Additionally, the recent FDA approval for the Acclaim CI's investigational device exemption highlights the company's commitment to innovation and further strengthens its market position within the hearing health sector.

Bears say

Envoy Medical reported a net loss of $6.2 million, resulting in an earnings per share (EPS) of $(0.29), which aligns closely with internal estimates but underperforms against consensus expectations, indicating persistent financial challenges. The company faces significant risks related to liquidity and balance sheet stability, alongside uncertainties surrounding the efficacy and regulatory approval of its product candidates, which could hinder revenue generation. Additionally, competitive pressures, macroeconomic factors, and shifting healthcare priorities may further complicate the company's prospects, casting a negative outlook on its stock performance.

COCH has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Envoy Medical Inc (COCH) Forecast

Analysts have given COCH a Strong Buy based on their latest research and market trends.

According to 1 analysts, COCH has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Envoy Medical Inc (COCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.